When a chronic wound has been properly cleaned, infection has been controlled, and systemic health barriers have been addressed, but the wound still isn't building new tissue at an adequate rate, skin substitutes and cellular tissue products (CTPs) can provide the biological support needed to restart progress.
These are bioengineered materials that supply structural scaffolding, growth factors, or living cellular components to the wound bed. They work with your body's repair mechanisms, not as replacements for them. And their success depends almost entirely on timing: the right product applied to a wound that isn't ready for it is an expensive dressing that won't perform.
The Products
Skin substitutes and CTPs come in several categories, each designed for different wound needs and healing phases:
Amniotic membrane allografts are derived from donated human placental tissue. They contain a rich extracellular matrix reservoir with anti-inflammatory proteins and growth factors that modulate the wound environment and promote tissue repair. These are commonly used for diabetic foot ulcers and venous leg ulcers that have moved into the building phase but need additional biological support. Application is typically weekly or biweekly over a course of four to eight weeks.
Dermal substitutes provide a three-dimensional scaffold (a "neodermis") that your body's cells can migrate into and populate with new tissue. These are often used for deep wounds where a significant amount of dermal tissue has been lost. In some cases, a split-thickness skin graft is applied on top once the neodermis has integrated.
Acellular matrices provide structural collagen support and, in some formulations, bind excess proteases (the enzymes that break down new tissue in chronic wounds). They are used in wounds where protease activity is a documented barrier to healing.
Cultured cell constructs contain living tissue components that actively secrete cytokines and growth factors into the wound bed. These products can help activate wound edge cells that have become senescent (biologically stalled) in chronic wounds.
The phase-gated approach. We do not apply skin substitutes or CTPs until the wound meets specific readiness criteria. Systemic barriers must be corrected: protein intake at 1.2 to 1.5 grams per kilogram per day minimum, HbA1c below 7.5 percent, adequate oxygenation, and anemia addressed. Local barriers must be controlled: pressure offloaded, edema compressed, perfusion adequate, and infection eliminated. Applying an advanced biologic product before these conditions are met leads to graft failure.
Who It Helps
Skin substitutes are considered for chronic wounds that have not achieved adequate progress despite at least four weeks of consistent, appropriate wound care. The typical candidate has a wound that is clean and free of infection, has adequate blood supply, and has had systemic health factors (blood sugar, nutrition, circulation) optimized, yet tissue growth has plateaued.
Common candidates include diabetic foot ulcers, venous leg ulcers, and pressure injuries that have completed the cleaning phase and entered the building phase but are not generating granulation tissue at a sufficient rate.
If your wound has failed to reduce by at least 40 percent in area within four weeks of proper care, a skin substitute may be the appropriate next step.
Your Visit
Here's what a typical skin substitute application looks like.
Skin substitute application is performed in our clinic. The wound bed is assessed and prepared, often with debridement to ensure a clean surface.
The product is applied directly to the wound and covered with a secondary dressing. The procedure is typically painless and takes 15 to 30 minutes. For amniotic allografts and cultured cell constructs, applications are usually repeated weekly or biweekly. For dermal substitutes, a single application may be followed by a period of integration before additional procedures.
We monitor the wound closely after each application, looking for measurable progress. The benchmark is 30 to 50 percent wound area reduction within four to six weeks of starting CTP therapy. If that benchmark isn't met, we reassess the wound, the product selection, and whether any systemic or local barriers have re-emerged. Continued application of a product that isn't producing results is not in your interest.
A traditional skin graft uses your own skin, harvested from a donor site on your body, to cover a wound. Skin substitutes are bioengineered products made from donated human tissue, animal-derived collagen, or cultured cells. They do not require a donor site surgery and are designed to support your body's natural repair process rather than replace tissue directly.
These products work by supporting your body's healing biology. If the wound still harbors infection, if blood sugar is uncontrolled, if nutrition is inadequate, or if the wound bed hasn't been properly debrided, the product cannot integrate effectively. Preparing the wound first is what allows the biologic to succeed.
This depends on the product and your wound's response. Amniotic allografts are typically applied weekly or biweekly for four to eight weeks. Dermal substitutes may require a single application followed by monitoring. Your clinician tracks measurable wound reduction at each visit and adjusts the plan based on results.
Most insurance plans, including Medicare, cover FDA-regulated skin substitutes for qualifying chronic wounds that have not responded to standard care. Our team handles the documentation and prior authorization process.
If measurable progress isn't observed within four to six weeks, we reassess. This may involve switching to a different product, re-evaluating systemic health factors, performing additional debridement, or adjusting other elements of the treatment plan. We do not continue therapy that isn't producing results.
Request a consultation and let our team determine whether your wound is ready for advanced tissue therapy.